Low level evidence supporting the choice of optimal multimodality treatment approach in patients with stage IIIA NSCLC– Ain’t no mountain high enough…. to keep me getting to you

Author:

Jeremic Branislav,Gomez-Caamano Antonio,Dubinsky Pavol,Cihoric NikolaORCID,Igrutinovic Ivan,Videtic Gregory

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference7 articles.

1. Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: a multi-institutional study by the oncologic group for the study of lung cancer (Spanish radiation oncology society);Counago;Lung Cancer,2018

2. Evidence for health decision making - beyond randomized, controlled trials;Frieden;N Engl. J. Med.,2017

3. Radiotherapy plus chemotherapy with orwithout surgical resection for stage III non-small-cell lung cancer: a phase IIIrandomised controlled trial;Albain;Lancet,2009

4. Combined modality therapy in stage IIIA nonsmall cell lung cancer: clarity or confusion despite the highest level of evidence?;Jeremic;J. Radiat. Res.,2017

5. Neoadjuvant chemoradiotherapy or chemotherapyfollowed by surgery is superior to that followed by definitive chemoradiation orradiotherapy in stage IIIA (N2) nonsmall-cell lung cancer: a meta-analysis and systematic review;Xu;Oncol. Targets Ther.,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3